Zoetis Just Confirmed What Every Front Desk Already Knows

Fewer clients are booking appointments, the ones who do are asking more questions before they say yes, and Zoetis just cut its 2026 outlook because of it.

If you've felt like your schedule has more open slots than it used to, you're not imagining it. Zoetis, one of the biggest names in animal health, just told investors the same thing your practice manager has been telling you all year: fewer pets are coming through the door.

The company posted second quarter revenue of $2.5 billion. That sounds like a big number until you realize it's basically flat year over year and actually down 1% once you strip out currency effects. CEO Kristin Peck didn't sugarcoat it either, calling out weakness specifically in the U.S. companion animal side of the business.

Two things are driving it, according to the earnings call. Visits are down, and the pet owners who do show up are being pickier about what they say yes to. That combination hits everything from vaccines and preventives to the diagnostics and prescriptions that keep a lot of practices financially healthy.

Pet owners aren't disappearing. They're just getting a lot more selective about where their money goes.

Chief Executive Officer Kristin Peck said the quarter fell short of the company's expectations amid declining veterinary clinic visits, more selective spending by pet owners and greater promotional activity from competitors. Zoetis lowered its full-year outlook, now expecting organic operational revenue to decline 3% to 1% and adjusted net income to decline 9% to 5%.

Peck said veterinary clinic visits continued a multiyear decline, while price increases in pet care have outpaced broader consumer inflation. Pet owners have become more selective in their spending, with clinic revenue shifting toward urgent and emergency care and premium preventative and chronic-care products facing pressure,

Dermatology, of All Places, Is Getting Crowded

Apoquel and Cytopoint built a huge chunk of Zoetis's dermatology business, and for years that category felt untouchable. Not anymore. New entrants are chipping away at that dominance, and Zoetis flagged dermatology specifically as an area that took a hit this quarter.For clinicians, more options in derm isn't a bad thing. Competition tends to mean better pricing and more tools in the toolbox for chronic allergy patients. For the manufacturers who built empires on a couple of blockbuster drugs, it means a much harder fight to hold market share.

The Outlook Just Got Worse, Not Better

Zoetis walked its full year guidance down. The company now expects organic revenue to fall somewhere between 1% and 3% for 2026, with adjusted net income dropping 5% to 9%. Adjusted earnings per share still climbed to $1.87, up 4%, but that's largely thanks to share buybacks rather than the business actually growing.

Maybe the most telling line from the call wasn't about the quarter that already happened. It was about July. Zoetis said trends hadn't stabilized yet, meaning this isn't a one-off rough stretch they're brushing off. Add roughly $60 to $65 million in expected foreign exchange headwinds and the picture gets even tighter.

It's Not All Bad News

Diagnostics grew 12%. Livestock grew 11%. International markets outperformed the U.S. companion animal segment. If your practice has leaned into in-house diagnostics and earlier disease detection, this earnings call is basically validation that you're building in the right direction, even while exam room traffic slows down.

What This Actually Means for Your Practice

Zoetis is one company, not a stand-in for the entire profession. But when one of the largest animal health companies in the world says visits are down and clients are getting choosier, that's a signal worth paying attention to at the practice level too.

Pet owners still love their animals just as much as they always have. What's changed is how carefully they're deciding when to come in, what services they'll approve, and which products actually make it home in the carrier. That puts more pressure on every team member to explain the why behind a recommendation, especially for preventive care, diagnostics, and anything chronic.

The growth story the industry has been telling itself for the last several years, more pets, more spending, more of everything, may be entering a new chapter. Clients aren't gone. They're just asking harder questions before they open their wallets, and practices that can answer those questions clearly are the ones that will keep their schedules full.

Source: MarketBeat, "Zoetis Q2 Earnings Call Highlights," August 9, 2026.